Matthew Bresnahan
Partner
-
Co-leader of Firmwide Patent Strategy Practice and Leader of the Southern California Team
Matt and his team of more than 40 patent attorneys and patent agents in the San Diego and Century City offices are outside IP counsel to over 50 life sciences companies, including many public companies listed on the NASDAQ exchange, within the biotechnology, therapeutic, genomics, and medical device fields, primarily in Southern California. Matt also leads the firm’s practice of over 160 patent attorneys and agents worldwide.
-
Legal Advisor to Innovative Life Sciences Companies in Southern California
Matt represents the likes of public companies Mirador Therapeutics, Sidewinder Therapeutics, NILO Therapeutics, Halia Therapeutics, ImmunityBio, PKx Bio, Belite Bio, Bright Peak Therapeutics, Empirico, Iambic Therapeutics, Octant, Scithera, SRT Therapeutics, Whitehawk, Myriad Genetics, RxSight, Cardiac Dimensions, Q’Apel, and CytoVale in key IP strategy, patent prosecution, and IP matters related to public company offering and SEC reporting.
-
Thought Leadership
A leader in the broader life sciences community, Matt serves as Vice Chairman of the Executive Board of Directors of Biocom California, where he also chairs the Nominating and Governance Committee; as a member of the Board of Directors of the SoCal Alliance; and as a Board of Governors member and adjunct professor at the University of San Diego School of Law, where he established the Wilson Sonsini Expanding Opportunities in Life Sciences Scholarship.
Matthew J. Bresnahan is a partner at Wilson Sonsini Goodrich & Rosati and one of the nation’s leading patent attorneys serving the life sciences industry. He co-leads the firm’s Patent and Innovations Department and is a leader of Wilson Sonsini’s life sciences practice in collaboration with the heads of multiple practice groups. Based in San Diego, Matt manages a sophisticated Southern California team of more than 40 patent attorneys and patent agents in the San Diego and Century City offices.
For two decades, Matt has advised leading biotechnology, therapeutics, medical device, and diagnostics companies on patent strategy, portfolio development, and IP-driven business growth. He serves as outside general IP counsel to an extensive client base and regularly guides companies through high-stakes IP diligence, financings, licensing transactions, IPOs, M&A, and strategic IP litigation. His work encompasses “bet-the-company” patent matters, freedom-to-operate analyses, and inter partes review (IPR) proceedings, as well as advising boards and executive teams on patent and life sciences business strategy. Matt is widely regarded for his ability to translate complex scientific and commercial objectives into durable, business-aligned intellectual property strategies that enable life sciences innovators to discover, develop, and deliver transformative therapies and treatments to the patients that need them the most.
Under Matt’s leadership, the San Diego patent team has grown significantly and is the cornerstone of Wilson Sonsini’s national life sciences practice. Matt and his team have developed and executed patent strategies for numerous biotech companies over his 20-year career, including strategies that have resulted in over $30 billion in M&A and licensing consideration in the past five years alone. Matt has created and overseen the implementation by his team of the patent strategy for more than 40 regulated life sciences products that have undergone clinical trials, including many that are now commercial.
Matt is recognized in Chambers USA: America’s Leading Lawyers for Business (2022-2025) among the top 30 patent attorneys in California, where clients describe him as “extremely effective as an IP lawyer in both execution and advice.” He is also ranked in the IAM Patent 1000 (2019-2025) as “recommended by peers for his creative thinking around complex strategic issues” and has received many awards throughout his career.
Experience
Matthew J. Bresnahan is a partner at Wilson Sonsini Goodrich & Rosati and one of the nation’s leading patent attorneys serving the life sciences industry. He co-leads the firm’s Patent and Innovations Department and is a leader of Wilson Sonsini’s life sciences practice in collaboration with the heads of multiple practice groups. Based in San Diego, Matt manages a sophisticated Southern California team of more than 40 patent attorneys and patent agents in the San Diego and Century City offices.
For two decades, Matt has advised leading biotechnology, therapeutics, medical device, and diagnostics companies on patent strategy, portfolio development, and IP-driven business growth. He serves as outside general IP counsel to an extensive client base and regularly guides companies through high-stakes IP diligence, financings, licensing transactions, IPOs, M&A, and strategic IP litigation. His work encompasses “bet-the-company” patent matters, freedom-to-operate analyses, and inter partes review (IPR) proceedings, as well as advising boards and executive teams on patent and life sciences business strategy. Matt is widely regarded for his ability to translate complex scientific and commercial objectives into durable, business-aligned intellectual property strategies that enable life sciences innovators to discover, develop, and deliver transformative therapies and treatments to the patients that need them the most.
Under Matt’s leadership, the San Diego patent team has grown significantly and is the cornerstone of Wilson Sonsini’s national life sciences practice. Matt and his team have developed and executed patent strategies for numerous biotech companies over his 20-year career, including strategies that have resulted in over $30 billion in M&A and licensing consideration in the past five years alone. Matt has created and overseen the implementation by his team of the patent strategy for more than 40 regulated life sciences products that have undergone clinical trials, including many that are now commercial.
Matt is recognized in Chambers USA: America’s Leading Lawyers for Business (2022-2025) among the top 30 patent attorneys in California, where clients describe him as “extremely effective as an IP lawyer in both execution and advice.” He is also ranked in the IAM Patent 1000 (2019-2025) as “recommended by peers for his creative thinking around complex strategic issues” and has received many awards throughout his career.
Education
- J.D., University of San Diego School of Law, 2007
- B.S., Biochemistry, California Polytechnic State University, San Luis Obispo, 2004
Associations and Memberships
- Member, Board of Directors, Biocom California
- Member, American Bar Association
- Member, American Intellectual Property Law Association
- Member, Los Angeles Intellectual Property Law Association
- Member, San Diego Intellectual Property Law Association
Honors
- Named among San Diego Business Journal’s 2025 “Leaders of Influence in Life Sciences”
- Named in the 2022-2025 editions of Chambers USA: America's Leading Lawyers for Business, in which sources describe him as having been “extremely effective as an IP lawyer in both execution and advice”
- Named in the 2019-2026 editions of the IAM Patent 1000: The World’s Leading Patent Professionals, in which he is “recommended by peers for his creative thinking around tricky strategic issues” in representation of a “swath of Southern California life sciences companies”
- Named to the 2015, 2016, and 2017 San Diego "Rising Stars" lists published by Super Lawyers magazine (top 2.5 percent of all attorneys in California under 40 years of age)
- Featured in a cover article titled "Students for Startups" in the University of San Diego School of Law alumni magazine (The Advocate, Winter 2012)
- Named a San Diego Daily Transcript Young Attorney in 2009
- Honored with the Wiley W. Manuel Award for Pro Bono Legal Services by the State Bar of California, 2009
Admissions
- State Bar of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., University of San Diego School of Law, 2007
- B.S., Biochemistry, California Polytechnic State University, San Luis Obispo, 2004
Associations and Memberships
- Member, Board of Directors, Biocom California
- Member, American Bar Association
- Member, American Intellectual Property Law Association
- Member, Los Angeles Intellectual Property Law Association
- Member, San Diego Intellectual Property Law Association
Honors
- Named among San Diego Business Journal’s 2025 “Leaders of Influence in Life Sciences”
- Named in the 2022-2025 editions of Chambers USA: America's Leading Lawyers for Business, in which sources describe him as having been “extremely effective as an IP lawyer in both execution and advice”
- Named in the 2019-2026 editions of the IAM Patent 1000: The World’s Leading Patent Professionals, in which he is “recommended by peers for his creative thinking around tricky strategic issues” in representation of a “swath of Southern California life sciences companies”
- Named to the 2015, 2016, and 2017 San Diego "Rising Stars" lists published by Super Lawyers magazine (top 2.5 percent of all attorneys in California under 40 years of age)
- Featured in a cover article titled "Students for Startups" in the University of San Diego School of Law alumni magazine (The Advocate, Winter 2012)
- Named a San Diego Daily Transcript Young Attorney in 2009
- Honored with the Wiley W. Manuel Award for Pro Bono Legal Services by the State Bar of California, 2009
Admissions
- State Bar of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office
Lead IP Counsel for the Following Select Active Clients
Therapeutics
- Mirador Therapeutics in connection with its platform and clinical stage therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation and financing (including its most recent $250 million Series B round) in support of its modalities in clinical development for autoimmune and anti-inflammatory diseases and related companion diagnostic programs.
- Iambic Therapeutics in connection with its AI-drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, several partnerships with large biopharmaceutical companies, and financings (including its most recent $130 million Series C round) in support of its modalities in clinical development for various therapeutic targets.
- ImmunityBio (NASDAQ: IBRX) in connection with its commercial biologics therapeutic asset IP strategy, including IP matters related to its public company offerings (including its $207 million IPO and more recent follow-on and ATM offerings), SEC reporting/disclosure obligations relating to IP, IP aspects of its strategic transactions with multiple major pharmaceutical companies, IP litigation and dispute resolution/settlement agreements, and FDA and USPTO advice in connection with its approval of its cytokine peptide fusion Anktiva® biologic oncology product franchise (including Patent Term Extension (PTE) counseling and representation before the agencies).
- NILO Therapeutics in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation, spin-out from Columbia University, and financing (including its most recent $100 million Series A round) in support of its modalities designed to restore immune homeostasis.
- Empirico in connection with its AI-drug discovery platform and clinical stage siRNA therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, strategic partnerships (including its most recent collaboration with GSK), and financings in support of its modalities in clinical development for various therapeutic targets.
- Belite Bio (NASDAQ: BLTE) in connection with its therapeutic ophthalmic assets IP strategy (including its lead anti-RBP4 small molecule that recently completed phase 3 clinical trials for Stargardt’s disease), IP matters related to its public company offerings (including its most recent $350 million follow-on offering), global patent prosecution, and IP matters related to its formation, spin-out from Columbia University, IPO, and subsequent follow-on offerings in support of its modalities in clinical development for ophthalmic diseases (including geographic atrophy and AMD).
- Whitehawk (NASDAQ: WHWK) in connection with its antibody-drug-conjugates (ADCs) therapeutic asset IP strategy, global patent prosecution, including IP matters related to its formation and public company offerings, SEC reporting/disclosure obligations relating to IP, and IP aspects of its strategic transactions with multinational pharma partners.
- PKx Bio in connection with its platform therapeutic IP strategy and patent drafting and prosecution of key company patents, development of its licensing strategy and plans, and key IP litigation with a competitor.
- Scithera in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets and modalities undisclosed), global patent prosecution, and IP matters related to its formation, spin-out, and financings.
- Halia Therapeutics in connection with its drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, several partnerships with large biopharmaceutical companies, and financings (including its most recent $130 million Series C round) in support of its modalities in clinical development for various therapeutic targets.
- SRT Therapeutics in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets and modalities undisclosed), global patent prosecution, and IP matters related to its formation, spin-out, financings, and agreements/collaborations.
- Juvena in connection with its AI-drug discovery platform and clinical stage peptide therapeutic assets IP strategy, global patent prosecution, and IP matters related to its formation, partnerships (including its most recent strategic collaboration with Eli Lilly), and financings (including its most recent $33.5 million Series B financing) in support of its modalities in clinical development for metabolic and myopathic diseases.
- Sidewinder Therapeutics in connection with its platform and clinical stage antibody-drug-conjugates (ADCs) therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation, partnerships, and financings.
- Bright Peak Therapeutics in connection with its platform and multispecific biologic clinical stage therapeutic assets IP strategy, global patent prosecution, and IP matters related to its formation, partnerships, and financings.
- Octant in connection with its AI-drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, spin-out from UCLA, partnerships with large biopharmaceutical companies, and financings (including more than $100 million to date) in support of its modalities for various therapeutic targets including genetic diseases, oncology, and metabolic diseases.
- Glo Pharma in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial peptide products for skin applications.
- Biograph55 in connection with its IP strategy, global patent prosecution, and IP matters related to its spin-out from UCLA and venture capital financings in support of its biologic therapeutic product pipeline.
- RevOpsis in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its multimeric antibody biologic therapeutic product pipeline.
- Prometheus Biosciences (NASDAQ: RXDX prior to acquisition) in connection with its IP strategy, global patent prosecution, and IP matters related to its acquisition by Merck for $10.8 billion in 2023, and earlier private and public company offerings (including its $190 million IPO) and SEC reporting obligations in support of its autoimmune and anti-inflammatory therapeutics and companion diagnostic programs with the lead TL1A monoclonal antibody product having completed phase 2 clinical studies prior to acquisition.
- Oncternal Therapeutics (NASDAQ: ONCT prior to assets being acquired) in connection with its antibody-drug-conjugates (ADCs), monoclonal antibodies (mAbs), and cell therapy IP strategy, including IP matters related to public company offerings (including its going public transaction) and SEC reporting in support of its biologic therapeutic product pipeline, including the creation and implementation of the IP strategy for its spin-out VelosBio, which was acquired by Merck in 2020 for $2.75 billion, primarily for its ROR1-targeted antibody-drug conjugate (ADC) that is now in phase 3 studies after showing 100 percent response rate on phase 2.
- ALASTIN Skincare in connection with its commercial TriHex platform technology IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial peptide products for aesthetic medicine and eventual sale to Galderma for $500 million in 2021.
Genomics
- Myriad Genetics (NASDAQ: MYGN) in connection with confidential IP matters.
- Seek Labs in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings and agreements in support of its diagnostic and CRISPR therapeutics.
- DermTech (NASDAQ: DMTK prior to being taken private) in connection with its IP strategy, global patent prosecution, and IP matters related to its public company offerings (including its going public transaction) and SEC reporting obligations in support of its commercial melanoma and skin cancer detection Dx tests and product pipeline.
- Nucleix in connection with its IP strategy, global patent prosecution, and partnering agreements for its pipeline of non-invasive diagnostic testing products.
Medical Devices
- RxSight (NASDAQ: RXST) in connection with its global IP strategy and IP matters related to its public company offerings (including its $120 million IPO and follow-on offerings) and SEC reporting obligations in support of its Intraocular Lens (IOL), Light Delivery Device (LDD), and Light Adjustable Lens (LAL) commercial medical device technologies.
- Cardiac Dimensions in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its clinical Carillon Mitral Contour System (a minimally invasive, catheter-based device designed to treat functional mitral regurgitation (FMR) by reshaping the mitral valve annulus from the coronary sinus).
- Q’Apel in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial and clinical medical devices for neurovascular access to treat stroke and complex neurovascular procedures.
- Cytovale in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial IntelliSep ® sepsis test, an FDA-cleared, AI-driven diagnostic tool launched in 2023 for rapid, under-10-minute sepsis detection in emergency departments
- Tempo Therapeutics in connection with its IP strategy, global patent prosecution, and licensing agreements focused on its clinical-stage regenerative medicine medical device products.
- Theradaptive with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its clinical-stage biologic therapeutic product pipeline.
- Auxilium Biotechnologies with its IP strategy, global patent prosecution, and IP matters related to its spin-out from UCSD and financings in support of its clinical stage regenerative medicine medical device products.
Research Institutions
- Cedars-Sinai Medical Center in connection with IP strategy and strategic patent prosecution for spin-out companies from the institution.
- La Jolla Institute for Immunology in connection with its IP strategy and strategic patent prosecution for spin-out companies from the institution.
- Ellison Institute in connection with IP planning and strategy for its spin-out from USC.
- Creation of multiple life science company spin-outs from each of the major academic institutions in Southern California.
Matters
Lead IP Counsel for the Following Select Active Clients
Therapeutics
- Mirador Therapeutics in connection with its platform and clinical stage therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation and financing (including its most recent $250 million Series B round) in support of its modalities in clinical development for autoimmune and anti-inflammatory diseases and related companion diagnostic programs.
- Iambic Therapeutics in connection with its AI-drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, several partnerships with large biopharmaceutical companies, and financings (including its most recent $130 million Series C round) in support of its modalities in clinical development for various therapeutic targets.
- ImmunityBio (NASDAQ: IBRX) in connection with its commercial biologics therapeutic asset IP strategy, including IP matters related to its public company offerings (including its $207 million IPO and more recent follow-on and ATM offerings), SEC reporting/disclosure obligations relating to IP, IP aspects of its strategic transactions with multiple major pharmaceutical companies, IP litigation and dispute resolution/settlement agreements, and FDA and USPTO advice in connection with its approval of its cytokine peptide fusion Anktiva® biologic oncology product franchise (including Patent Term Extension (PTE) counseling and representation before the agencies).
- NILO Therapeutics in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation, spin-out from Columbia University, and financing (including its most recent $100 million Series A round) in support of its modalities designed to restore immune homeostasis.
- Empirico in connection with its AI-drug discovery platform and clinical stage siRNA therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, strategic partnerships (including its most recent collaboration with GSK), and financings in support of its modalities in clinical development for various therapeutic targets.
- Belite Bio (NASDAQ: BLTE) in connection with its therapeutic ophthalmic assets IP strategy (including its lead anti-RBP4 small molecule that recently completed phase 3 clinical trials for Stargardt’s disease), IP matters related to its public company offerings (including its most recent $350 million follow-on offering), global patent prosecution, and IP matters related to its formation, spin-out from Columbia University, IPO, and subsequent follow-on offerings in support of its modalities in clinical development for ophthalmic diseases (including geographic atrophy and AMD).
- Whitehawk (NASDAQ: WHWK) in connection with its antibody-drug-conjugates (ADCs) therapeutic asset IP strategy, global patent prosecution, including IP matters related to its formation and public company offerings, SEC reporting/disclosure obligations relating to IP, and IP aspects of its strategic transactions with multinational pharma partners.
- PKx Bio in connection with its platform therapeutic IP strategy and patent drafting and prosecution of key company patents, development of its licensing strategy and plans, and key IP litigation with a competitor.
- Scithera in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets and modalities undisclosed), global patent prosecution, and IP matters related to its formation, spin-out, and financings.
- Halia Therapeutics in connection with its drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, several partnerships with large biopharmaceutical companies, and financings (including its most recent $130 million Series C round) in support of its modalities in clinical development for various therapeutic targets.
- SRT Therapeutics in connection with its platform and pre-clinical stage therapeutic assets IP strategy (targets and modalities undisclosed), global patent prosecution, and IP matters related to its formation, spin-out, financings, and agreements/collaborations.
- Juvena in connection with its AI-drug discovery platform and clinical stage peptide therapeutic assets IP strategy, global patent prosecution, and IP matters related to its formation, partnerships (including its most recent strategic collaboration with Eli Lilly), and financings (including its most recent $33.5 million Series B financing) in support of its modalities in clinical development for metabolic and myopathic diseases.
- Sidewinder Therapeutics in connection with its platform and clinical stage antibody-drug-conjugates (ADCs) therapeutic assets IP strategy (targets undisclosed), global patent prosecution, and IP matters related to its formation, partnerships, and financings.
- Bright Peak Therapeutics in connection with its platform and multispecific biologic clinical stage therapeutic assets IP strategy, global patent prosecution, and IP matters related to its formation, partnerships, and financings.
- Octant in connection with its AI-drug discovery platform and clinical stage small molecule therapeutic IP strategy, global patent prosecution, and IP matters related to its formation, spin-out from UCLA, partnerships with large biopharmaceutical companies, and financings (including more than $100 million to date) in support of its modalities for various therapeutic targets including genetic diseases, oncology, and metabolic diseases.
- Glo Pharma in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial peptide products for skin applications.
- Biograph55 in connection with its IP strategy, global patent prosecution, and IP matters related to its spin-out from UCLA and venture capital financings in support of its biologic therapeutic product pipeline.
- RevOpsis in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its multimeric antibody biologic therapeutic product pipeline.
- Prometheus Biosciences (NASDAQ: RXDX prior to acquisition) in connection with its IP strategy, global patent prosecution, and IP matters related to its acquisition by Merck for $10.8 billion in 2023, and earlier private and public company offerings (including its $190 million IPO) and SEC reporting obligations in support of its autoimmune and anti-inflammatory therapeutics and companion diagnostic programs with the lead TL1A monoclonal antibody product having completed phase 2 clinical studies prior to acquisition.
- Oncternal Therapeutics (NASDAQ: ONCT prior to assets being acquired) in connection with its antibody-drug-conjugates (ADCs), monoclonal antibodies (mAbs), and cell therapy IP strategy, including IP matters related to public company offerings (including its going public transaction) and SEC reporting in support of its biologic therapeutic product pipeline, including the creation and implementation of the IP strategy for its spin-out VelosBio, which was acquired by Merck in 2020 for $2.75 billion, primarily for its ROR1-targeted antibody-drug conjugate (ADC) that is now in phase 3 studies after showing 100 percent response rate on phase 2.
- ALASTIN Skincare in connection with its commercial TriHex platform technology IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial peptide products for aesthetic medicine and eventual sale to Galderma for $500 million in 2021.
Genomics
- Myriad Genetics (NASDAQ: MYGN) in connection with confidential IP matters.
- Seek Labs in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings and agreements in support of its diagnostic and CRISPR therapeutics.
- DermTech (NASDAQ: DMTK prior to being taken private) in connection with its IP strategy, global patent prosecution, and IP matters related to its public company offerings (including its going public transaction) and SEC reporting obligations in support of its commercial melanoma and skin cancer detection Dx tests and product pipeline.
- Nucleix in connection with its IP strategy, global patent prosecution, and partnering agreements for its pipeline of non-invasive diagnostic testing products.
Medical Devices
- RxSight (NASDAQ: RXST) in connection with its global IP strategy and IP matters related to its public company offerings (including its $120 million IPO and follow-on offerings) and SEC reporting obligations in support of its Intraocular Lens (IOL), Light Delivery Device (LDD), and Light Adjustable Lens (LAL) commercial medical device technologies.
- Cardiac Dimensions in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its clinical Carillon Mitral Contour System (a minimally invasive, catheter-based device designed to treat functional mitral regurgitation (FMR) by reshaping the mitral valve annulus from the coronary sinus).
- Q’Apel in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial and clinical medical devices for neurovascular access to treat stroke and complex neurovascular procedures.
- Cytovale in connection with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its commercial IntelliSep ® sepsis test, an FDA-cleared, AI-driven diagnostic tool launched in 2023 for rapid, under-10-minute sepsis detection in emergency departments
- Tempo Therapeutics in connection with its IP strategy, global patent prosecution, and licensing agreements focused on its clinical-stage regenerative medicine medical device products.
- Theradaptive with its IP strategy, global patent prosecution, and IP matters related to its venture capital financings in support of its clinical-stage biologic therapeutic product pipeline.
- Auxilium Biotechnologies with its IP strategy, global patent prosecution, and IP matters related to its spin-out from UCSD and financings in support of its clinical stage regenerative medicine medical device products.
Research Institutions
- Cedars-Sinai Medical Center in connection with IP strategy and strategic patent prosecution for spin-out companies from the institution.
- La Jolla Institute for Immunology in connection with its IP strategy and strategic patent prosecution for spin-out companies from the institution.
- Ellison Institute in connection with IP planning and strategy for its spin-out from USC.
- Creation of multiple life science company spin-outs from each of the major academic institutions in Southern California.
Select Publications
- Co-author with A. Umpierre and F. Tian, “Broad Genus Patents Must Be Enabled over the Full Scope of the Claims,” Wilson Sonsini Alert, May 24, 2023
Insights
Select Publications
- Co-author with A. Umpierre and F. Tian, “Broad Genus Patents Must Be Enabled over the Full Scope of the Claims,” Wilson Sonsini Alert, May 24, 2023
Recent Insights
News Articles
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Learn More
Recent Events
WSGR Events
Biotech's New Playbook: Spinouts and Optionality
Biotechnology companies are increasingly using single-asset spinouts as a way to create value, though the approach can be complex. This afternoon forum will examine considerations to strategically design and execute a successful spinout. Attendees will gain insight into the legal foundations of these transactions, including tax considerations, patent strategy, IP allocation, and structural design. The program will also explore the broader business drivers behind spinout decisions—such as capital formation, strategic focus, partnership alignment, governance, and long-term value creation.
Learn More
Speaking Engagements
OIS Ignite: Ophthalmology Startup Workshop — San Diego
Wilson Sonsini is pleased to participate in the inaugural OIS Ignite Startup Workshop taking place in San Diego on November 20, 2025. OIS Ignite is a focused, full-day program designed to support ophthalmology start-ups as they navigate the most critical challenges from early development through commercialization. Through expert panels, real-world examples, and peer exchange, this event addresses the complex journey of bringing innovation to market, across both anterior and posterior segment therapies.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.